14.04.2011 • NewsHenkelJoaquin AlmuniaP&G

Unilever, P&G Fined €315.2 million For Price Fixing

Consumer goods giants Unilever and Procter & Gamble were fined €315.2 million ($456 million) by EU regulators on Wednesday for fixing washing powder prices in eight EU countries.

Germany's Henkel, which alerted the European Commission to the cartel in laundry detergents, was not fined. The penalty for Unilever was €104 million while P&G was fined €211.2 million.

As part of the Commission's settlement procedure, the EU watchdog had cut the fines by 10% in return for the firms' admissions that they participated in the cartel, which the Commission had dubbed "purity" in its investigation.

"By acknowledging their participation in the cartel, the companies enabled the Commission to swiftly conclude its investigation," EU Competition Commissioner Joaquin Almunia said in a statement.

The fines had also been reduced under the Commission's leniency program related to voluntary disclosure of information.

World No.1 household products producer P&G owns the Tide, Gain and Era brands of washing powder while Anglo-Dutch Unilever makes detergent products under the brand names Omo and Surf. Henkel owns the Persil brand in most of Europe, while Unilever owns it in Britain, Ireland and France.

The cartel operated in Belgium, France, Germany, Greece, Italy, Portugal, Spain and the Netherlands between 2002 and 2005, the regulator said.

Unilever said it had used the investigation findings to tighten up its internal procedures, while adding that the fine was covered by provisions made in its 2010 results.

"All key managers in Europe have been retrained on the European competition rules and are well placed to participate fully in industry-wide environmental initiatives," the company  said in a statement.

Henkel said it found out about the cartel activity during internal compliance audits in 2008 and immediately informed the regulators.

The Commission can fine companies up to 10% of annual turnover for breaching competition EU rules. This is the third EU decision using the settlement procedure after cases in the electronic chipmaking and animal feed sectors last year.

The EU watchdog raided the three firms in June 2008 on suspicion of price fixing, and also sought information from U.S.-based household products firm Sara Lee. It has imposed fines close to €12 billion  on cartels in the five years to 2010.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.